To further validate our findings in vivo and vitro, we first performed experiments to find out whether TLR9 agonist alone or combination with anti-PD-L1 influence proliferation or apoptosis of HCC cells in vitro. This evidence concerns the gene TLR9 and hepatocellular carcinoma.